Fig. 1: NURR1 exhibits an upregulation in clinical prostate cancer tissues and prostate cancer cell lines.

A, B Transcriptome analysis of two microarray datasets of clinical prostate cancer tissues reveal that NURR1 exhibits an increased expression pattern in prostate cancer. C, D Immunohistochemical analysis of NURR1 in prostate cancer tissue microarrays. C Representative micrographs show the NURR1-immunostained tissue spots of BPH and prostate cancer tissues. More intense nuclear immunosignals of NURR1 were detected in cancer cells than that in glandular epithelial cells in BPH and adjacent normal tissues. Magnification, × 400; bars = 500 μm. D NURR1-IRS analysis. Results showed that high Gleason score (GS) prostate cancer lesions expressed significant higher NURR1 expression than in normal or BPH tissues. E NURR1 immunoblots. Multiple prostate cancer cell lines expressed higher levels of NURR1 than immortalized prostatic epithelial cells BPH-1. *P < 0.05; **P < 0.001 versus normal or BPH.